Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.

Two Americans and a Briton won the 2018 Nobel Prize for Chemistry for harnessing the power of evolution to generate novel proteins.

Johnson & Johnson vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company’s products gave them ovarian cancer by arguing the plaintiffs’ science was flawed and the case should not have been heard in Missouri.

The Vilcek Foundation announced the winners of the 2018 Vilcek Prizes in Biomedical Science. Awarded annually, the prizes call attention to the breadth of immigrant contributions to science in the United States. In parallel, the Vilcek Foundation also awards prizes for immigrant accomplishments in the arts.

Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.

Pfizer launched a six-person biotech startup, SpringWorks Therapeutics, with a $103 million Series A financing. Joining Pfizer in funding the company was Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and LifeArc, formerly known as MRC Technology.

In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market.

Science needs champions. That is the belief of Johnson & Johnson’s Seema Kumar, vice president of Innovation, Global Health and Science Policy Communication. And that is a belief being harnessed by a new J&J initiative that celebrates the legacy of Dr. Paul Janssen, one of the most prolific scientific innovators of the past century.

People who spend less time in deep, rapid eye movement (REM) sleep may be more likely to develop dementia than individuals who get better quality rest, a recent study suggests.

Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.